Moexipril HCl

Moexipril HCl is a potent orally active nonsulfhydrylangiotensin converting enzyme (ACE) inhibitor, used for the treatment of hypertension and congestive heart failure. (In Vitro) :Moexipril hydrochloride is devoid of anti-inflammatory properties and has no effect on platelet function.Moexipril hydrochloride hydrolyzes to Moexiprilat, and Moexiprilat inhibits ACE in guinea pig serum as well as on purified ACE from rabbit lung with IC50s of 2.6 and 4.9 nM, respectively.Moexipril hydrochloride (0.01 nM-0.1 mM) exhibits high potency against both plasma ACE and purified ACE from rabbit lung, with IC50s of 2.7 mM and 0.165 mM, respectively.Moexipril hydrochloride (0-100 μM, 24 h) significantly reduced the percentage of damaged neurons in a dose-dependent manner.Moexipril hydrochloride (0-100 μM, 24 h) significantly attenuates Fe2+/3+-induced neurotoxicity.Moexipril hydrochloride dose not cause significant changes in the percentage of apoptotic neurons. (In Vivo) :Moexipril hydrochloride can not cross the blood-brain barrier.Moexipril hydrochloride (3 mg/kg, 30 mg/kg and 10 mg/kg, respectively; p.o.; once daily; 5 days) exhibits the a dose-dependent and antihypertensive effects in renal hypertensive rats, spontaneously hypertensive rats and perinephritic hypertensive dogs, respectively.Moexipril hydrochloride (0.3 mg/kg, i.p.) significantly reduces the infarct area on the mouse brain surface in NMRI mice.Moexipril hydrochloride (0.1 mg/kg, i.p.) significantly attenuates the cortical infarct volume in Long-Evans rats.